All the Patients undergoing General Anesthesia and the patients who are having Chronic Obstructive Pulmonary Disease will be considered for this study. The Volume consumption of Sevoflurane will be studied in accordance with age, sex, duration , type of surgery, site of surgery and BMI.The volume consumption of sevoflurane is compared with Chronic Obstructive Pulmonary Disease and Normal Patients .

开始日期2024-01-01

申办/合作机构

Medtronic Spine LLC

NCT04778826 / Unknown statusN/AIIT

Immune Response of Patients Following Thoracoscopic Lobectomy Along With Bilateral Transcervical Mediastinal Lymphadenectomy and Patients Receiving VATSLOB Together With Standard Unilateral Mediastinal Lymphadenectomy

Any kind of anatomical lung resection for lung cancer with curative intent has to be accompanied by formal mediastinal lymph node dissection. Video-assisted mediastinoscopic lymphadenectomy through a cervical access (VAMLA) along with thoracoscopic lobectomies in the same setting offers improved radicality through bilateral mediastinal dissection, provide accurate staging, does not require single lung ventilation and hence ideally supports the concept of minimally invasive surgery.
Due to the VAMLA associated radicality, the investigator believes that using of VAMLA along with lobectomy could improve the oncological outcome of lung cancer patients. Furthermore, the absence of single lung ventilation during VAMLA could attenuate the surgically induced immunosuppression.

开始日期2020-10-01

申办/合作机构

Medtronic Spine LLC

NCT03356626 / CompletedN/AIIT

Comparison of Perioperative Outcomes Between Bipolar Sealing Device and Ultrasonic Shears During Laparoscopic Gastrectomy for Early Gastric Cancer

To find out which instrument can be much better for laparoscopic gastrectomy among Harmonic scalpel, Ligasure Maryland, Thunderbeat
comparing postoperative CRP level in each group

开始日期2018-03-12

申办/合作机构

Seoul National University Hospital

[+1]

100 项与 Medtronic Spine LLC 相关的临床结果

登录后查看更多信息

0 项与 Medtronic Spine LLC 相关的专利（医药）

登录后查看更多信息

项与 Medtronic Spine LLC 相关的文献（医药）

2017-12-01·Journal of orthopaedic surgery and research3区 · 医学

Injectable and compression-resistant low-viscosity polymer/ceramic composite carriers for rhBMP-2 in a rabbit model of posterolateral fusion: a pilot study

3区 · 医学

ArticleOA

作者: Talley, Anne D ; Shimko, Daniel ; Wenke, Joseph C ; Zienkiewicz, Katarzyna J ; McGough, Madison A P ; Guelcher, Scott A ; Kalpakci, Kerem ; Shiels, Stefanie M

BACKGROUND:

The challenging biological and mechanical environment of posterolateral fusion (PLF) requires a carrier that spans the transverse processes and resists the compressive forces of the posterior musculature. The less traumatic posterolateral approach enabled by minimally invasive surgical techniques has prompted investigations into alternative rhBMP-2 carriers that are injectable, settable, and compression-resistant. In this pilot study, we investigated injectable low-viscosity (LV) polymer/composite bone grafts as compression-resistant carriers for rhBMP-2 in a single-level rabbit PLF model.

METHODS:

LV grafts were augmented with ceramic microparticles: (1) hydrolytically degradable bioactive glass (BG), or (2) cell-degradable 85% β-tricalcium phosphate/15% hydroxyapatite (CM). Material properties, such as pore size, viscosity, working time, and bulk modulus upon curing, were measured for each LV polymer/ceramic material. An in vivo model of posterolateral fusion in a rabbit was used to assess the grafts' capability to encourage spinal fusion.

RESULTS:

These materials maintained a working time between 9.6 and 10.3 min, with a final bulk modulus between 1.2 and 3.1 MPa. The LV polymer/composite bone grafts released 55% of their rhBMP-2 over a 14-day period. As assessed by manual palpation in vivo, fusion was achieved in all (n = 3) animals treated with LV/BG or LV/CM carriers incorporating 430 μg rhBMP-2/ml. Images of μCT and histological sections revealed evidence of bone fusion near the transverse processes.

CONCLUSION:

This study highlights the potential of LV grafts as injectable and compression-resistant rhBMP-2 carriers for posterolateral spinal fusion.

2016-08-01·Clinical spine surgery4区 · 医学

Two-Year Evaluation of the X-STOP Interspinous Spacer in Different Primary Patient Populations With Neurogenic Intermittent Claudication Because of Lumbar Spinal Stenosis

4区 · 医学

Article

作者: Hsu, Emily H. ; Hsu, Ken Y. ; Zucherman, James F. ; Resnick, Daniel K. ; Skidmore, Grant A. ; Hartjen, Charles A.

Study Design::

Multicenter, prospective single-arm study in patients diagnosed with neurogenic intermittent claudication because of lumbar spinal stenosis.

Objective::

To collect data from 2 different primary patient populations, new participants meeting entry criteria [Continued Access Program (CAP)], or subjects who had been randomly assigned to nonsurgical management in the pivotal Investigational Device Exemption study and failed to respond upon study completion [Crossover Study (COS)].

Summary of Background Data::

The X-STOP interspinous spacer is a minimally invasive treatment option for neurogenic intermittent claudication shown to improve pain, physical functioning, and/or overall quality of life.

Methods::

Fifty-five subjects were enrolled, 42 in CAP and 13 in COS. Zurich Claudication Questionnaire (ZCQ) success rates were obtained based on the number of subjects achieving a threshold level of success. Mean SF-36 domain scores were compared with baseline using repeated measures analysis of variance.

Results::

Eighty percent of subjects completed the study. At 2 years, 26/43 subjects (60.5%) achieved clinically significant improvement in the Symptom Severity domain, 25/43 (58.1%) achieved clinically significant improvement in the Physical Function domain, and 31/44 (70.5%) achieved clinically significant improvement in the Patient Satisfaction domain of the ZCQ. Statistically significant improvement in mean scores was obtained in all physical domains of the SF-36 (with the exception of General Health) at 24 months. Mean improvement in ZCQ and SF-36 scores was not as pronounced in the COS cohort compared with the CAP cohort. The most frequently reported device-related or treatment-related adverse event was stenosis pain reported by 3 subjects.

Conclusions::

Overall data are consistent with the randomized pivotal Investigational Device Exemption trial. On the basis of the COS cohort which was subject to several additional years of failed conservative treatment, overall success rates do not improve as greatly in patients with long-standing lumbar spinal stenosis symptoms.

2011-07-01·Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research1区 · 医学

Balloon kyphoplasty for the treatment of acute vertebral compression fractures: 2-year results from a randomized trial

1区 · 医学

Article

作者: Richard Eastell ; Leonard Bastian ; Steven Boonen ; Steven R Cummings ; Douglas Wardlaw ; Jan Van Meirhaeghe ; Karen Talmadge ; Jonas Ranstam ; John B Tillman

Abstract:

Vertebral fractures are often painful and lead to reduced quality of life and disability. We compared the efficacy and safety of balloon kyphoplasty to nonsurgical therapy over 24 months in patients with acute painful fractures. Adults with one to three vertebral fractures were randomized within 3 months from onset of pain to undergo kyphoplasty (n = 149) or nonsurgical therapy (n = 151). Quality of life, function, disability, and pain were assessed over 24 months. Kyphoplasty was associated with greater improvements in Short-Form 36 (SF-36) Physical Component Summary (PCS) scores when averaged across the 24-month follow-up period compared with nonsurgical therapy [overall treatment effect 3.24 points, 95% confidence interval (CI) 1.47–5.01, p = .0004]; the treatment difference remained statistically significant at 6 months (3.39 points, 95% CI 1.13–5.64, p = .003) but not at 12 months (1.70 points, 95% CI −0.59 to 3.98, p = .15) or 24 months (1.68 points, 95% CI −0.63 to 3.99, p = .15). Greater improvement in back pain was observed over 24 months for kyphoplasty (overall treatment effect −1.49 points, 95% CI −1.88 to −1.10, p < .0001); the difference between groups remained statistically significant at 24 months (−0.80 points, 95% CI −1.39 to −0.20, p = .009). There were two device-related serious adverse events in the second year that occurred at index vertebrae (a spondylitis and an anterior cement migration). There was no statistically significant difference between groups in the number of patients (47.5% for kyphoplasty, 44.1% for control) with new radiographic vertebral fractures; fewer fractures occurred (∼18%) within the second year. Compared with nonsurgical management, kyphoplasty rapidly reduces pain and improves function, disability, and quality of life without increasing the risk of additional vertebral fractures. The differences from nonsurgical management are statistically significant when averaged across 24 months. Most outcomes are not statistically different at 24 months, but the reduction in back pain remains statistically significant at all time points. © 2011 American Society for Bone and Mineral Research.

项与 Medtronic Spine LLC 相关的新闻（医药）

2024-07-29

·Business Wire

PK MED Appoints Yvonne Bokelman as Chairman of the Board of Directors

LYON, France--( BUSINESS WIRE )-- PK MED, a French biotech company founded in 2019 by Truffle Capital, announces the appointment of Yvonne Bokelman as Chairman of the Board of Directors. Yvonne has held a number of executive positions in industry, most recently as Chief Executive Officer of Alyve Medical, a start-up in the musculoskeletal space. Prior to that she spent more than a decade with Zimmer Biomet, a world leading orthopedic company, in a variety of leadership positions, including as President and General Manager in the last several years, and she was with Medtronic Spine & Biologics for six years as well. Early in her career, she worked in hospital administration and spent several years as Executive Vice President at QuadraMed, a healthcare IT company. Yvonne has an MBA and is a Fellow in the American College of Healthcare Executives. In her career, Yvonne has acquired a unique executive experience in medical device, hospitals, consulting, and healthcare information technology. She is an accomplished business operations executive, market access expert, transformational and strategical leader, who has been involved in numerous product launches and commercialization of devices and therapies. Yvonne Bokelman has a history of commercializing solutions that help patients treat musculoskeletal pain. Her experience will be particularly useful in developing PKM-01, an innovative intra-articular injection for the treatment of gout and pain relief. This solution for gout, as well as treatments discovered to tackle other conditions, testify to PK MED's outstanding potential, which Yvonne Bokelman is delighted to support. Philippe Pouletty, M.D., founder of PK MED and CEO of Truffle Capital said: “ We are very proud of PK MED’s achievements. It is now time to welcome new talent with strong industry, market access and international experience to the Board of Directors of PK MED, and I am delighted to offer the Chairmanship to Yvonne Bokelman who has a stellar career in healthcare and the life sciences industry.” Yvonne Bokelman, Chairman of the Board of Directors of PK MED, said : " I’m looking forward to my new role with the team of PK MED at such a significant time in the company’s development. PK MED has tremendous potential and I thank the members of the Board of Directors for their trust.” About PK MED PK MED is a French biotechnology company, founded in 2019 by Truffle Capital, developing injectable smart implants for drug release in rheumatology and cell homing for bone marrow transplantation. PK MED's unique expertise and technological know-how enable evolving existing systemic treatments into new, safer and more effective patented local therapies. PK MED has developed a portfolio of projects in indications where medical needs are high, starting with gout (PKM-01) and Hematopoietic Stem Cells transplants (PKM-02).

高管变更

2006-04-14

·BioSpace

Kyphon Inc. To Report First Quarter 2006 Financial Results On April 27, 2006

SUNNYVALE, Calif., April 13 /PRNewswire-FirstCall/ -- Kyphon Inc. today announced that it will host a conference call on Thursday, April 27, 2006 at 2:00 p.m. Pacific Time to discuss the company's results for its first quarter ended March 31, 2006. Kyphon will issue a press release detailing the company's financial results for the quarter that day following the close of the market. Richard W. Mott, President and Chief Executive Officer, and Arthur T. Taylor, Chief Operating Officer & Chief Financial Officer, will host the call. A live webcast of the call will be available from the Investor Relations section of the company's corporate Web site at . The call will be archived on this site for a minimum of two months. An audio replay of the call will also be available beginning from 6:00 p.m. Pacific Time on Thursday, April 27, 2006, until 12:00 a.m. Pacific Time on Thursday, May 18, 2006. To access the replay, dial (888) 203-1112 (U.S.) or (719) 457-0820 (International) and enter the access code 7088154. About Kyphon Kyphon develops and markets medical devices designed to restore spinal function using minimally invasive technologies. The company's KyphX line of products are used in balloon kyphoplasty, a minimally invasive procedure to treat spinal fractures caused by osteoporosis or cancer. For more information, visit Kyphon's Web site at . NOTE: Kyphon and KyphX are registered trademarks of Kyphon Inc. KYPHE Kyphon Inc. CONTACT: Julie D. Tracy, Vice President, Investor Relations and CorporateMarketing of Kyphon Inc, +1-408-548-6500, or jtracy@kyphon.com Web site:

财报

100 项与 Medtronic Spine LLC 相关的药物交易

登录后查看更多信息

100 项与 Medtronic Spine LLC 相关的转化医学

登录后查看更多信息